Bimagrumab: The Muscle-Preserving Weight-Loss Antibody — Evidence Review

Bimagrumab is the obesity drug that does the one thing GLP-1 medications cannot: it builds muscle while it burns fat. It is not a GLP-1, not a peptide hormone, and not an appetite suppressant. It is a fully human monoclonal antibody that blocks the activin type II receptors (ActRII) on skeletal muscle — a brake-release that drives muscle growth and, as a downstream effect, large losses of body fat. In the pivotal phase 2 trial in adults with type 2 diabetes and obesity, bimagrumab cut total body fat mass by about 20.5% while increasing lean mass by 3.6% over 48 weeks (Heymsfield 2021^[1]). That body-composition signature is the mirror image of what semaglutide and tirzepatide produce, where roughly a quarter to 40% of the weight lost is lean tissue. The reason bimagrumab matters in 2026 is that question exactly: as tens of millions take GLP-1s, the muscle-loss concern has moved from footnote to headline — and bimagrumab is the leading candidate to fix it. It is investigational, not FDA-approved, and now developed by Eli Lilly (via the 2023 Versanis Bio acquisition). The BELIEVE phase 2 trial of bimagrumab plus semaglutide just read out (Heymsfield 2026 Nature Medicine^[2]). Here is the honest evidence.

The honest summary

• It is an antibody, not a hormone. Bimagrumab is a fully human monoclonal antibody that blocks the activin type II receptors (ActRIIA/ActRIIB) on skeletal muscle. Blocking ActRII releases the natural myostatin/activin brake on muscle growth, so muscle hypertrophies — and fat mass falls as a metabolic consequence (Heymsfield 2021^[1]). This is a fundamentally different mechanism from GLP-1 receptor agonism, which works through appetite and satiety.
• It is investigational, not approved. As of 2026 bimagrumab is not approved by the FDA, EMA, or any other major regulator for obesity or any other indication. It is in phase 2/3-stage development. You cannot get it on prescription or from any compounding pharmacy.
• The body-composition signature is unique. In the phase 2 trial (Heymsfield 2021^[1]), bimagrumab cut fat mass by 20.5% (-7.5 kg) and raised lean mass by 3.6% (+1.7 kg) over 48 weeks vs essentially no change on placebo. Total body weight fell only 6.5% — modest — precisely because the muscle gain offsets some of the scale weight. The drug is about quality of weight loss, not quantity.
• The GLP-1 tie-in is the whole story. GLP-1 drugs cause large weight loss, but roughly 25–40% of that loss is lean (muscle) tissue. Bimagrumab is being developed as a muscle-preserving add-on. The BELIEVE phase 2 trial (Heymsfield 2026 Nature Medicine^[2]) tested bimagrumab, semaglutide, and the combination head-to-head.
• What BELIEVE showed. At 48 weeks, body weight fell -9.3 kg on high-dose bimagrumab alone, -14.2 kg on semaglutide 2.4 mg alone, and -17.8 kg on the combination, vs -3.3 kg on placebo (Heymsfield 2026^[2]). The combination beat semaglutide on total weight — and the antibody's mechanism is designed to shift that loss toward fat and away from muscle.
• Developer lineage: originally Novartis → spun out to Versanis Bio → acquired by Eli Lilly in 2023. Bimagrumab now sits inside the same pipeline as Zepbound and retatrutide.

What bimagrumab actually is, pharmacologically

Skeletal muscle growth is held in check by a family of signaling proteins — myostatin and the activins — that act through the activin type II receptors (ActRIIA and ActRIIB) on the muscle-cell surface. When myostatin binds ActRII, it switches on a SMAD pathway that suppresses muscle protein synthesis. It is a brake. Bimagrumab is a fully human monoclonal antibody that binds and blocks ActRII, preventing myostatin and activin from docking. With the brake released, muscle fibers hypertrophy. This was the original rationale for developing bimagrumab in muscle-wasting conditions (sarcopenia, cancer cachexia, inclusion-body myositis).

The surprise that redirected the whole program was metabolic. In those early muscle-wasting studies, participants did not just gain muscle — they lost substantial fat mass and improved their insulin sensitivity. ActRII blockade turned out to shift body composition on both axes at once: more lean tissue, less adipose tissue. Because skeletal muscle is the body's largest glucose sink, growing it improves glycemic control independent of any effect on appetite. That dual signature — build muscle, shed fat, improve blood sugar — is what moved bimagrumab from a rare-disease drug into the obesity pipeline (Heymsfield 2021^[1]).

The pivotal phase 2 trial: Heymsfield 2021 JAMA Network Open

The landmark proof-of-concept was a double-masked, placebo-controlled, 48-week phase 2 randomized trial in 75 adults with type 2 diabetes and a BMI of 28–40 (Heymsfield 2021^[1], NCT03005288, conducted while bimagrumab was still a Novartis asset). Participants received intravenous bimagrumab (10 mg/kg, up to 1200 mg) or placebo every four weeks for 48 weeks; both arms got diet and exercise counseling. The primary endpoint was change in total body fat mass.

The results were striking and lopsided in a way no GLP-1 trial produces. Versus placebo at week 48, bimagrumab delivered: fat mass -20.5% (-7.5 kg) vs -0.5%; lean mass +3.6% (+1.7 kg) vs -0.8%; waist circumference -9.0 cm vs +0.5 cm; HbA1c -0.76 percentage points vs -0.04; and total body weight -6.5% (-5.9 kg) vs -0.8% (all P < .001 except HbA1c P = .005). The headline to internalize: the scale moved only 6.5%, but body fat fell more than 20% — because the simultaneous gain in muscle held up the total weight. Safety was consistent with prior bimagrumab studies; the characteristic adverse events were mild muscle spasms and occasional diarrhea, not the gastrointestinal profile of GLP-1s.

BELIEVE: bimagrumab plus semaglutide (Heymsfield 2026 Nature Medicine)

The trial that defines bimagrumab's role for the GLP-1 era is BELIEVE (Heymsfield 2026 Nature Medicine^[2], NCT05616013) — the first study to put bimagrumab, semaglutide, and the combination head-to-head. It was a double-blind, placebo-controlled phase 2 trial in 507 adults with obesity (BMI ≥30, or ≥27 with a complication; diabetes excluded), randomized to nine arms across placebo, bimagrumab (10 or 30 mg/kg IV every 12 weeks), semaglutide (1.0 or 2.4 mg weekly), and their combinations, for 48 weeks, with an open-label extension to 72 weeks.

Least-squares mean change in body weight at week 48 was -9.3 kg on bimagrumab 30 mg/kg alone, -14.2 kg on semaglutide 2.4 mg alone, and -17.8 kg on the high-dose combination, versus -3.3 kg on placebo (all P < 0.001 vs placebo), with continued improvement through week 72 (Heymsfield 2026^[2]). Two things matter here. First, the combination produced more total weight loss than semaglutide alone — the mechanisms stack. Second, and the reason the trial exists, bimagrumab's contribution is engineered to come from fat while defending muscle; the adverse-event profiles were complementary too (bimagrumab: muscle spasms, diarrhea, acne; semaglutide: nausea, diarrhea, constipation, fatigue). Safety was consistent with the known profiles of both drugs.

Magnitude and quality: bimagrumab vs the approved drugs

Read the chart carefully, because the obvious reading is the wrong one. On total scale weight, bimagrumab monotherapy (-6.5%) looks far weaker than semaglutide (STEP-1, Wilding 2021^[3]) or tirzepatide (SURMOUNT-1, Jastreboff 2022^[4]). But scale weight is the wrong yardstick for this drug. Bimagrumab's fat-mass loss was about 20.5% — in the same league as the best GLP-1s — while it simultaneously added 1.7 kg of muscle. A semaglutide or tirzepatide user typically loses muscle along with fat. Bimagrumab is not competing on how far the scale moves; it is competing on what the lost weight is made of. The BELIEVE combination arm is the practical synthesis: GLP-1-class total weight loss with the antibody steering the composition toward fat.

Body composition: the metric that actually distinguishes the classes

Why does the muscle question matter beyond aesthetics? Skeletal muscle is metabolically active tissue: it is the primary site of insulin-stimulated glucose disposal, a major contributor to resting energy expenditure, and the structural basis of strength and fall-prevention as people age. Losing it during weight loss can lower resting metabolic rate (making weight regain easier), worsen physical function, and is a particular concern in older adults already at risk for sarcopenia. A drug that defends or grows muscle while fat falls is addressing the part of GLP-1 weight loss that the GLP-1 mechanism itself cannot.

Where bimagrumab sits in development and what is still unknown

Bimagrumab's path has been winding: discovered and advanced at Novartis, spun into the startup Versanis Bio, then acquired by Eli Lilly in 2023 specifically for the obesity and muscle-preservation opportunity. With BELIEVE reading out positively in 2026 (Heymsfield 2026^[2]), the molecule now sits alongside Zepbound and retatrutide in Lilly's portfolio as the candidate muscle-preserving partner. Several questions remain genuinely open. The most important: in the combination setting, exactly how much of the GLP-1-associated lean-mass loss does bimagrumab prevent, measured by DXA, and does that translate into preserved physical function and lower regain — outcomes that only larger, longer phase 3 trials can establish. Dosing and route are also unsettled: bimagrumab in trials is given intravenously every 4–12 weeks, which is a heavier administration burden than a once-weekly self-injected pen.

On safety, the bimagrumab-specific adverse events seen so far — muscle spasms, mild diarrhea, acne, and small reversible changes in pancreatic enzyme and electrolyte labs in earlier studies — are different from and largely non-overlapping with the GLP-1 gastrointestinal profile, which is part of why the combination is attractive. But long-term safety of sustained ActRII blockade in a large, otherwise-healthy obesity population is not yet established. Until phase 3 data exist, every magnitude and safety statement here should be read as provisional.

How patients and clinicians should think about bimagrumab today

Bimagrumab is not prescribable and not available from any legitimate source in 2026 — not by prescription, not from a compounding pharmacy, and not (despite what some peptide marketplaces imply) as a research chemical. It is a complex monoclonal antibody manufactured inside Lilly's clinical supply chain, not a peptide that can be synthesized and relabeled. Anything sold online as "bimagrumab" should be treated as fraudulent or, at best, unverified. The honest answer to "can I get bimagrumab?" today is no.

For people on a GLP-1 worried about muscle loss right now, the evidence-based levers that are available are resistance training and adequate protein intake — not an unapproved antibody. Bimagrumab is the most promising pharmacologic answer on the horizon, and the BELIEVE data make a strong mechanistic case, but it is a phase 2/3-stage investigational drug. The realistic timeline for any approval, if phase 3 confirms the body-composition benefit, is years out, not months. For now, bimagrumab is a reason for optimism about the next generation of obesity treatment — not a treatment you can use.

Related research and tools

• GLP-1 pipeline overview — the broader landscape of investigational obesity drugs, the context bimagrumab competes in
• Semaglutide and muscle mass loss — how much lean tissue Wegovy and Ozempic users actually lose, the problem bimagrumab is designed to solve
• Tirzepatide muscle loss and lean mass — the lean-mass evidence for Zepbound and Mounjaro
• GLP-1 muscle-loss prevention protocol — the resistance-training and protein strategies available today while bimagrumab is still investigational
• Ozempic muscle loss and lean-mass protection — practical body-composition protection on semaglutide
• Amycretin pipeline evidence — Novo's unimolecular GLP-1/amylin co-agonist, another leading pipeline molecule

Important disclaimer. Bimagrumab is an investigational drug not approved by the FDA, EMA, or any other regulator for obesity or any indication. The data summarized here come from phase 2 trials (including BELIEVE); magnitude, body-composition, and safety estimates will move as phase 3 data accumulate. This article is educational and does not constitute medical advice or an endorsement to use any unapproved product marketed as "bimagrumab." All PMIDs were verified live against the PubMed E-utilities API on 2026-06-01.

Last verified: 2026-06-01. Next review: every 6 months, or sooner if Lilly publishes a phase 3 bimagrumab readout or any regulatory submission is announced.